| 1399 |
National Cancer Institute |
Html |
en |
Nausea and Vomiting Related to Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about nausea and vomiting as complications of cancer or its treatment. Approaches to the management of nausea and vomiting are discussed. |
| cancer treatment | 0.379171 |
| chemotherapy session | 0.416704 |
| past chemotherapy treatments | 0.404595 |
| motion sickness | 0.3776 |
| chemotherapy | 0.552867 |
| PDQ cancer information | 0.463652 |
| chemotherapy treatment | 0.441369 |
| late nausea | 0.506038 |
| anticipatory nausea | 0.711385 |
| clinical trials | 0.378644 |
| vomiting | 0.900093 |
| Vomiting Related | 0.471509 |
| cancer information summary | 0.41736 |
| patients | 0.393418 |
| earlier chemotherapy session | 0.400031 |
| treatment room | 0.360635 |
| NCI’s PDQ | 0.353745 |
| nausea | 0.98576 |
| NCI PDQ cancer | 0.3835 |
| radiation therapy | 0.495467 |
| antinausea drugs | 0.406187 |
| involuntary body functions | 0.353798 |
| certain chemotherapy drugs | 0.416814 |
| following treatment factors | 0.366128 |
|
| radiation therapy treatments | 0.356798 |
| treatment | 0.558325 |
| gastrointestinal tract | 0.416866 |
| following table | 0.366172 |
| delayed nausea | 0.530808 |
| Cancer Information Service | 0.360675 |
| following patient factors | 0.352013 |
| previous chemotherapy sessions | 0.394908 |
| patient | 0.370352 |
| treatment clinical trials | 0.357831 |
| National Cancer Institute | 0.420163 |
| Palliative Care Editorial | 0.381728 |
| new treatment | 0.358991 |
| chronic nausea | 0.490418 |
| drugs | 0.426328 |
| Cancer Care page | 0.352418 |
| Care Editorial Board | 0.382615 |
| chemotherapy sessions | 0.400414 |
| PDQ summary | 0.40058 |
| Nausea section | 0.481663 |
| cancer information summaries | 0.360345 |
| comprehensive cancer information | 0.360198 |
| cancer therapy | 0.357442 |
| acute nausea | 0.484601 |
|
CLICK HERE |
| 1517 |
National Cancer Institute |
Html |
en |
Pancreatic Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of pancreatic cancer. |
| cancer treatment | 0.45958 |
| malignant tumor cells | 0.419406 |
| body | 0.510954 |
| chemotherapy | 0.404222 |
| PDQ cancer information | 0.497348 |
| clinical trial search | 0.455776 |
| pancreas | 0.487969 |
| clinical trials | 0.753194 |
| nearby lymph nodes | 0.471943 |
| cancer information summary | 0.460465 |
| clinical trial | 0.646358 |
| cancer cells | 0.504208 |
| exocrine pancreatic cancer | 0.466193 |
| patients | 0.395936 |
| treatment clinical trial | 0.39568 |
| endocrine pancreatic cancer | 0.462275 |
| NCI PDQ cancer | 0.417319 |
| Pancreatic Cancer Treatment | 0.455234 |
| Treatment Editorial Board | 0.392271 |
| small intestine | 0.597674 |
| endocrine pancreas cells | 0.397632 |
| general cancer information | 0.404462 |
| treatment | 0.608368 |
| general information | 0.413544 |
| new cancer treatments | 0.400431 |
|
| NCI-supported cancer | 0.412236 |
| Cancer Information Service | 0.405331 |
| specific cancer cells | 0.402178 |
| pancreatic cancer | 0.933074 |
| pancreatic cancer spreads | 0.442487 |
| stage pancreatic cancer | 0.467555 |
| treatment clinical trials | 0.430898 |
| National Cancer Institute | 0.509295 |
| Pancreatic Neuroendocrine Tumors | 0.405468 |
| new treatment | 0.444026 |
| Radiation therapy | 0.523817 |
| Blood. The cancer | 0.396713 |
| PDQ summary | 0.454317 |
| cancer research process | 0.390975 |
| cancer clinical trials | 0.486763 |
| tumor | 0.448545 |
| high-energy sound waves | 0.434518 |
| cancer information summaries | 0.402821 |
| comprehensive cancer information | 0.402789 |
| internal radiation therapy | 0.390099 |
| cancer | 0.947965 |
| information | 0.519314 |
| standard treatment | 0.39251 |
| Recurrent pancreatic cancer | 0.47605 |
|
CLICK HERE |
| 1546 |
National Cancer Institute |
Html |
en |
AIDS-Related Lymphoma Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of AIDS-Related Lymphoma. |
| cancer treatment | 0.383886 |
| AIDS-Related Lymphoma Treatment | 0.393286 |
| cancer spreads | 0.326687 |
| malignant tumor cells | 0.309541 |
| body | 0.433918 |
| chemotherapy | 0.309155 |
| PDQ cancer information | 0.394743 |
| clinical trial search | 0.3032 |
| white blood cells | 0.3776 |
| clinical trials | 0.731846 |
| cancer information summary | 0.354741 |
| clinical trial | 0.454136 |
| AIDS-related peripheral/systemic lymphoma | 0.466219 |
| patients | 0.380662 |
| blood cells | 0.399358 |
| old blood cells | 0.295369 |
| AIDS-related lymphomas | 0.315773 |
| treatment clinical trial | 0.296684 |
| NCI PDQ cancer | 0.309251 |
| lymph nodes | 0.464743 |
| large B-cell lymphoma | 0.331734 |
| radiation therapy | 0.344733 |
| Treatment Editorial Board | 0.312981 |
| lymph node groups | 0.478813 |
| treatment | 0.574951 |
|
| swollen lymph nodes | 0.339153 |
| cancer cells | 0.476016 |
| lymph node group | 0.321747 |
| specific cancer cells | 0.306685 |
| AIDS-related non-Hodgkin lymphoma | 0.392687 |
| primary cns lymphoma | 0.430113 |
| treatment clinical trials | 0.33124 |
| National Cancer Institute | 0.355357 |
| aids-related lymphoma | 0.927549 |
| lymph vessels | 0.351707 |
| new treatment | 0.337577 |
| External radiation therapy | 0.327164 |
| B-cell immunoblastic lymphoma | 0.332379 |
| AIDS-related primary CNS | 0.358458 |
| bone marrow | 0.523968 |
| cancer clinical trials | 0.341952 |
| stage | 0.313358 |
| treatment options | 0.307053 |
| nervous system lymphoma | 0.295273 |
| cancer | 0.766753 |
| standard treatment | 0.309541 |
| lymph tissue | 0.333823 |
| body lymphoma | 0.323497 |
| Burkitt-like lymphoma | 0.311372 |
|
CLICK HERE |
| 1585 |
National Cancer Institute |
Html |
en |
Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Patient Version |
Multiple myeloma, plasmacytoma, lymphoplasmacytic lymphoma, and monoclonal gammopathy of undetermined significance (MGUS) are different types of plasma cell neoplasms. Find out about risk factors, symptoms, tests to diagnose, prognosis, stages, and treatment for these diseases. |
| red blood cells | 0.474629 |
| myeloma cells | 0.443938 |
| cancer treatment | 0.407402 |
| Myeloma treatment options | 0.373753 |
| biologic therapy | 0.382101 |
| blood -forming cells | 0.372128 |
| body | 0.40943 |
| type | 0.393577 |
| PDQ cancer information | 0.415525 |
| bone marrow aspiration | 0.378402 |
| clinical trial search | 0.419003 |
| white blood cells | 0.422631 |
| clinical trials | 0.689828 |
| mature blood cells | 0.378353 |
| abnormal plasma cells | 0.479263 |
| cancer information summary | 0.39289 |
| clinical trial | 0.492432 |
| stem cells | 0.378 |
| multiple myeloma | 0.975001 |
| patients | 0.39195 |
| blood cells | 0.516713 |
| plasma cell neoplasm | 0.43097 |
| radiation therapy | 0.450659 |
| Treatment Editorial Board | 0.365249 |
| General information | 0.366352 |
|
| treatment | 0.57038 |
| skeletal bone survey | 0.42368 |
| immature blood cells | 0.371472 |
| plasma cell tumor | 0.384236 |
| NCI-supported cancer | 0.3737 |
| cancer cells | 0.440163 |
| normal blood cells | 0.369334 |
| specific cancer cells | 0.38023 |
| diagnose multiple myeloma | 0.381187 |
| patient | 0.372697 |
| treatment clinical trials | 0.388849 |
| National Cancer Institute | 0.392841 |
| initial treatment | 0.372799 |
| new treatment | 0.406543 |
| plasma cells | 0.480204 |
| refractory multiple myeloma | 0.365057 |
| bone marrow | 0.582695 |
| healthy blood cells | 0.378266 |
| cells | 0.557939 |
| cancer clinical trials | 0.42623 |
| cancer | 0.627272 |
| information | 0.418087 |
| myeloma cells increases | 0.397071 |
| plasma cell neoplasms | 0.895903 |
|
CLICK HERE |
| 1621 |
National Cancer Institute |
Html |
en |
Ewing Sarcoma Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of Ewing sarcoma. |
| cancer treatment | 0.289749 |
| malignant tumor cells | 0.276208 |
| soft tissue | 0.253817 |
| body | 0.332426 |
| type | 0.219713 |
| chemotherapy | 0.237331 |
| treatments | 0.202586 |
| PDQ cancer information | 0.292839 |
| clinical trial search | 0.246556 |
| extraosseous Ewing sarcoma | 0.264218 |
| Ewing sarcoma spreads | 0.243807 |
| clinical trials | 0.704097 |
| Pediatric Treatment Editorial | 0.209616 |
| nearby lymph nodes | 0.208892 |
| cancer information summary | 0.25517 |
| clinical trial | 0.374839 |
| recurrent Ewing sarcoma | 0.335434 |
| stage Ewing sarcoma | 0.262403 |
| patients | 0.209976 |
| Soft Tissue Sarcoma | 0.20334 |
| childhood Ewing sarcoma | 0.227663 |
| CAR T-cell therapy | 0.238653 |
| NCI PDQ cancer | 0.207565 |
| Ewing sarcoma family | 0.264166 |
| radiation therapy | 0.525383 |
|
| Treatment Editorial Board | 0.214583 |
| treatment | 0.586815 |
| Ewing sarcoma | 0.925686 |
| Ewing sarcoma cells | 0.277555 |
| NCI-supported cancer | 0.206887 |
| cancer cells | 0.457951 |
| metastatic Ewing sarcoma | 0.365401 |
| specific cancer cells | 0.219988 |
| patient | 0.217481 |
| treatment clinical trials | 0.236708 |
| National Cancer Institute | 0.256904 |
| initial treatment | 0.212474 |
| effects cancer treatment | 0.221598 |
| new treatment | 0.271508 |
| bone | 0.246041 |
| metastatic tumor | 0.210193 |
| bone marrow | 0.235686 |
| Ewing tumor | 0.226375 |
| cancer clinical trials | 0.279951 |
| stem cell rescue | 0.32512 |
| tumor | 0.434783 |
| High-dose chemotherapy | 0.218893 |
| cancer | 0.820936 |
| standard treatment | 0.227171 |
|
CLICK HERE |
| 1638 |
National Cancer Institute |
Html |
en |
Essiac/Flor Essence (PDQ®)–Patient Version |
Essiac and Flor Essence are herbal tea mixtures first developed in Canada that are thought to remove toxins and poisons from the body and strengthen the immune system, although this has not been proven in cancer patients. Read about the history of Essiac and Flor Essence, the theory behind its use, and the results of laboratory, animal, and human studies. |
| Essiac formula | 0.502569 |
| peer-reviewed scientific journals | 0.490423 |
| cancer treatment | 0.454247 |
| cancer prevention | 0.375568 |
| Complementary Therapies Editorial | 0.416551 |
| Kill cancer cells | 0.376017 |
| breast cancer patient | 0.382628 |
| Drug Administration | 0.400504 |
| Cancer Information Specialist | 0.387931 |
| Flor Essence | 0.977313 |
| Flor Essence state | 0.48205 |
| herbal dietary supplements | 0.446297 |
| Flor Essence formulas | 0.482148 |
| Cancer Information Service | 0.448298 |
| Essiac | 0.851494 |
| Essiac herbal teas | 0.514938 |
| PDQ cancer information | 0.515287 |
| health tonics | 0.425459 |
| Cancer Complementary | 0.397385 |
| Flor Essence products | 0.478002 |
| CAM therapies | 0.376991 |
| prostate cancer cells | 0.376887 |
| Flor Essence tea | 0.479505 |
| National Cancer Institute | 0.598699 |
|
| studies | 0.410222 |
| Sloan-Kettering Cancer Center | 0.381887 |
| clinical trials | 0.491591 |
| Royal Cancer Commission | 0.384396 |
| alternative medicine | 0.441037 |
| health care | 0.376403 |
| cancer information summary | 0.466243 |
| alternative cancer therapies | 0.394811 |
| Federal Trade Commission | 0.379856 |
| clinical trial | 0.417042 |
| cancer cells | 0.389663 |
| Essiac/Flor Essence | 0.431725 |
| CAM cancer research | 0.383472 |
| herbal tea mixtures | 0.394707 |
| cancer patients | 0.424798 |
| NCI PDQ cancer | 0.416273 |
| cancer information database | 0.392781 |
| effects | 0.382227 |
| alternative therapies | 0.415163 |
| cancer information summaries | 0.394001 |
| Therapies Editorial Board | 0.400185 |
| cancer | 0.660273 |
| research studies | 0.398662 |
|
CLICK HERE |
| 1644 |
National Cancer Institute |
Html |
en |
Gerson Therapy (PDQ®)–Patient Version |
Expert-reviewed information summary about the use of the Gerson therapy as a treatment for people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only. |
| treatment | 0.476929 |
| cancer treatment | 0.426084 |
| cancer prevention | 0.384318 |
| Complementary Therapies Editorial | 0.435586 |
| Cancer Information Specialist | 0.399657 |
| Drug Administration | 0.382514 |
| body | 0.378493 |
| Cancer Information Service | 0.518118 |
| PDQ cancer information | 0.525476 |
| Cancer Complementary | 0.410407 |
| CAM therapies | 0.388339 |
| Gerson’s therapy | 0.456461 |
| treatment clinical trials | 0.381128 |
| Gerson therapy reports | 0.478587 |
| National Cancer Institute | 0.663474 |
| clinical trials | 0.562754 |
| Dr. Gerson | 0.569329 |
| alternative medicine | 0.46145 |
| health care providers | 0.421555 |
| health care | 0.444706 |
| cancer information summary | 0.471527 |
| Max B. Gerson | 0.46509 |
| Gerson Research Organization | 0.453179 |
| alternative cancer therapies | 0.404484 |
|
| Federal Trade Commission | 0.391653 |
| National Institutes | 0.385207 |
| clinical trial | 0.399404 |
| National Center | 0.376357 |
| CAM cancer research | 0.391227 |
| new treatment | 0.374685 |
| breast cancer prevention | 0.381892 |
| patients | 0.477683 |
| cancer patients | 0.443285 |
| Cancer Care page | 0.385186 |
| latest published information | 0.376378 |
| key parts | 0.39704 |
| NCI’s PDQ | 0.381863 |
| PDQ summary | 0.408051 |
| Integrative Health | 0.376266 |
| NCI PDQ cancer | 0.437412 |
| cancer information database | 0.407023 |
| alternative therapies | 0.430873 |
| cancer information summaries | 0.407395 |
| Therapies Editorial Board | 0.414248 |
| cancer | 0.692284 |
| gerson therapy | 0.948648 |
| cancer information | 0.545756 |
|
CLICK HERE |
| 1685 |
National Cancer Institute |
Html |
en |
Cannabis and Cannabinoids (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the use of Cannabis and cannabinoids in the treatment of cancer-related side effects, such as nausea and vomiting. |
| cannabinoid receptor CB2 | 0.721549 |
| cancer cell proliferation | 0.723514 |
| opioid-treated cancer patients | 0.721253 |
| lung cancer | 0.774703 |
| testicular germ cell | 0.736506 |
| Cannabis trials | 0.713054 |
| endogenous cannabinoids | 0.733591 |
| bladder cancer | 0.72104 |
| clinical trials | 0.71653 |
| cannabinoid receptors | 0.745589 |
| advanced cancer patients | 0.745457 |
| CBD oromucosal spray | 0.730536 |
| cancer cell invasiveness | 0.726743 |
| Cancer Res | 0.716198 |
| cancer patients | 0.801404 |
| Investigational New Drug | 0.714731 |
| non-small cell lung | 0.751006 |
| effects | 0.733811 |
| colorectal cancer cell | 0.727697 |
| cancer chemotherapy | 0.737056 |
| cannabinoids | 0.838589 |
| et al. | 0.767053 |
| treatment | 0.713465 |
| study | 0.761272 |
| CBD | 0.77215 |
|
| United States | 0.780596 |
| Cannabis plant | 0.728018 |
| orally administered Cannabis | 0.721336 |
| Cancer Epidemiol Biomarkers | 0.717008 |
| cancer cell lines | 0.803788 |
| cannabinoid receptor | 0.74565 |
| THC | 0.76674 |
| Cannabis extract | 0.739506 |
| lung cancer chemotherapy | 0.709535 |
| cancer cell invasion | 0.72445 |
| breast cancer cell | 0.789227 |
| Cancer pain results | 0.7118 |
| cancer pain | 0.721348 |
| open-label extension study | 0.709343 |
| advanced cancer | 0.748132 |
| cell death | 0.806928 |
| Abstract | 0.744659 |
| cannabis | 0.92504 |
| germ cell tumors | 0.735413 |
| medicinal Cannabis | 0.751597 |
| cell lung cancer | 0.728336 |
| Cannabis species | 0.726958 |
| cancer | 0.952946 |
| Guidelines recommend cannabinoids | 0.714742 |
|
CLICK HERE |
| 2111 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de esófago (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de esófago. |
| PDQ Exámenes | 0.728989 |
| Physician Data Query | 0.906997 |
| libre uso | 0.636785 |
| prevención revisa | 0.652274 |
| información ayuda | 0.682663 |
| vÃas respiratorias | 0.673206 |
|
| carcinoma epidermoide | 0.760269 |
| National Cancer Institute | 0.66546 |
| cáncer.ampliar esofagoscopÃa | 0.714851 |
| siguientes riesgos | 0.649549 |
| siguientes sumarios | 0.849506 |
| Instituto Nacional | 0.740034 |
|
CLICK HERE |
| 3438 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de estómago (gástrico) (PDQ®)–Versión para profesionales de salud |
Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de estómago (gástrico). |
| Offerhaus J | 0.113586 |
| Cancer Res Clin | 0.264444 |
| Cancer high-risk subjects | 0.263357 |
| mass screening | 0.365942 |
| Leung WK | 0.124317 |
| Kobayashi K | 0.11932 |
| American Cancer Society | 0.823817 |
| detección versus | 0.189954 |
| case-control study | 0.112022 |
| Tytgat GN | 0.125733 |
| CA Cancer | 0.258236 |
| Instituto Nacional | 0.144846 |
| PDQ Exámenes | 0.215492 |
| prospectively followed chinese | 0.229607 |
| Estados Unidos | 0.202827 |
| Yanaoka K | 0.108053 |
| biological agents | 0.104643 |
| Morson BC | 0.118473 |
| high risk | 0.121936 |
| repeated endoscopic screens | 0.228776 |
| Lancet Oncol | 0.24929 |
| mass screening program | 0.337333 |
| mass survey | 0.121584 |
| Gastrointestinal Tract | 0.130066 |
| Ma JL | 0.109737 |
|
| mass screening techniques | 0.150063 |
| Precancerous Lesions | 0.123357 |
| Barbara L | 0.103989 |
| Cancer Facts | 0.263557 |
| Pfeiffer R | 0.11257 |
| Costa Rica | 0.0971337 |
| detección darán | 0.220411 |
| Mathus-Vliegen EM | 0.121366 |
| Ubukata T | 0.120185 |
| National Cancer Institute | 0.793771 |
| Oka M | 0.099234 |
| gastric carcinoma | 0.217462 |
| Endoscopic screening during | 0.138672 |
| serum pepsinogen concentrations | 0.241325 |
| New York | 0.185957 |
| Clin Oncol | 0.132653 |
| Kitahara F | 0.112823 |
| Sherlock P | 0.239085 |
| X-ray screening seems | 0.130764 |
| serum pepsinogen | 0.612986 |
| using serum pepsinogen | 0.482271 |
| Sato T | 0.127922 |
| stomach cancer | 0.944477 |
| Wu MS | 0.109301 |
|
CLICK HERE |